Language :
English
中文
Zuo Xiao Cong
Home
Journal Publications
Research Projects
Books
Patents
Teaching
Honors and Awards
Recommended Ph.D.Supervisor
Recommended MA Supervisor
MOBILE Version
Journal Publications
Current position:
Home
>
Journal Publications
[1]Ling-Yun Zhou, Kun Liu, Wen-Jun Yin, Yue-Liang Xie, Jiang-Lin Wang, Shan-Ru Zuo, Zhi-Yao Tang, Yi-Feng Wu.Arginase2 mediates contrast-induced acute kidney injury via facilitating nitrosative stress in tubular cells.Redox Biology, 2023
[2]林小青, 尹文俊, 周凌云, 谢悦良, 汪江林.万古霉素联用哌拉西林他唑巴坦致急性肾损伤的研究进展.药物流行病学杂志, 2023
[3]向必晓, 谢悦良.粒细胞或粒细胞-巨噬细胞集落刺激因子致肺毒性临床特征分析.中南药学, 2023
[4]Wang, JL (Wang, Jianglin), Zhou, LY (Zhou, Lingyun), Yin, WJ (Yin, Wenjun), Hu, C (Hu, Can).Trends of the burden of type 2 diabetes mellitus attributable to high body mass index from 1990 to 2019 in China.FRONTIERS IN ENDOCRINOLOGY, 2023
[5]Deng, YX (Deng, Yi-Xuan), Liu, K (Liu, Kun), Qiu, QX (Qiu, Qun-Xiang), Tang, ZY (Tang, Zhi-Yao), Que, RM (Que, Rui-Man), Li, DK (Li, Dian-Ke), Gu, XR (Gu, Xu-Rui), GL (Zhou, Guang-Liang), Wu, YF (Wu, Yi-Feng), Zhou, LY (Zhou, Ling-Yun), Yin, WJ (Yin, Wen-Jun).Identification and validation of hub genes in drug induced acute kidney injury basing on integrated transcriptomic analysis.FRONTIERS IN IMMUNOLOGY, 2023
[6]周凌云, 邓晟, xuping, lixin, 颜滢, 欧阳林旗, 刘湘, 何鸽飞, 陈艳平, 史志华, 王安发, 黄宇, 王立新, 何益锋, 张继红, 郭艳.口服钙通道阻滞剂类药品临床综合评价专家共识(湖南).中国医院药学杂志, 2023
[7]Liu, K (Liu, Kun), Hu, C (Hu, Can), Yin, WJ (Yin, Wenjun), Zhou, LY (Zhou, Lingyun), Gu, XR (Gu, Xurui).An in vivo and in vitro model on the protective effect of cilnidipine on contrast-induced nephropathy via regulation of apoptosis and CaMKII/mPTP pathway.JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2023
[8]Piao, Huiling, Wu, Meiyu, Qin, Shuxia, Tang, Zhiyao, Zhou, Guangliang, Wan, Xiaomin.Trametinib for patients with recurrent low-grade serous ovarian cancer: A cost-effectiveness analysis.GYNECOLOGIC ONCOLOGY, 2023
[9]朴慧玲, 谷旭瑞, 周凌云, 周光亮, 蒋安琪, 谢悦良.4种低分子肝素预防骨科大手术静脉血栓栓塞症的网状Meta分析及药物经济学评价.中国临床药学杂志, 2022
[10]Xie, YL (Xie, Yue-liang), Jin, X (Jin, Xin), Yan, SS (Yan, Shan-shan), Wu, CF (Wu, Cui-fang), Xiang, BX (Xiang, Bi-xiao), Wang, H (Wang, Hui), Liang, W (Liang, Wu), Yang, BC (Yang, Bing-chang), Xiao, XF (Xiao, Xue-fei), Li, ZL (Li, Zhi-ling), Pei, Q (Pei, Qi), Peng, Y (Peng, Yue).Population pharmacokinetics of intravenous colistin sulfate and dosage optimization in critically ill patients.FRONTIERS IN PHARMACOLOGY, 2022
[11]周凌云, 汤志耀, 陈林华.案例教学结合客观结构化临床考试在临床药学专业本科课程教学中的应用.中国临床药学杂志, 2022
[12]Yang, HQ (Yang, Hui-qin), Yin, WJ (Yin, Wen-Jun), K (Liu, Kun), Liu, MC (Liu, Man-Cang).Renal safety evaluation of aspirin plus edaravone in patients with ischaemic stroke: a retrospective cohort study.BMJ OPEN, 2022
[13]尹文俊, 周凌云, 周颖玉, 周光亮, 朴慧玲, 刘昆, 谷旭瑞, 胡灿, 谢悦良.2015—2020年湖南省医疗机构肾毒性药物用药情况分析.中南药学, 2022
[14]JL (Wang, Jiang-lin), Yin, WJ (Yin, Wen-jun), Zhou, LY (Zhou, Ling-yun), Wang, YF (Wang, Ya-feng).Association Between Initiation, Intensity, and Cessation of Smoking and Mortality Risk in Patients With Cardiovascular Disease: A Cohort Study.FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021
[15]Yang, HQ (Yang, Hui-qin), Liu, MC (Liu, Man-cang), Yin, WJ (Yin, Wen-jun), Zhou, LY (Zhou, Ling-yun).Safety and Efficacy of Low Molecular Weight Heparin for Thromboprophylaxis in the Elderly: A Network Meta-Analysis of Randomized Clinical Trials.FRONTIERS IN PHARMACOLOGY, 2021
[16]Xie, YL (Xie, Yue-liang), Liu, JJ (Liu, Jing-jing), Peng, JF (Peng, Jin-fu), Li, YQ (Li, Ya-qian), Lin, YQ (Lin, Ya-qi), Pei, Q (Pei, Qi).The pharmacokinetic challenge of polymyxin B in critically ill patients with morbid obesity.JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2021
[17]陈林华, 周凌云, 李典坷, 汪江林, 尹文俊, 刘昆, 周格, 方伟进.不同低分子肝素预防房颤患者血栓性疾病有效性和安全性的网状Meta分析.中国循证医学杂志, 2021
[18]LY (Zhou, Ling-Yun), Yin, WJ (Yin, Wen-Jun), Zhao, J (Zhao, Jun), Zhang, BK (Zhang, Bi-Kui), Hu, C (Hu, Can), Liu, K (Liu, Kun), Wang, JL (Wang, Jiang-Lin), Zhou, G (Zhou, Ge), Chen, LH (Chen, Lin-Hua), Zuo, SR (Zuo, Shan-Ru), Xie, YL (Xie, Yue-Liang).A Novel Creatinine-Based Equation to Estimate Glomerular Filtration Rate in Chinese Population With Chronic Kidney Disease: Implications for DOACs Dosing in Atrial Fibrillation Patients.FRONTIERS IN PHARMACOLOGY, 2021
[19]尹文俊, 陈林华, 杨慧琴.两种造影剂致老年患者造影剂肾病风险比较.医药导报, 2021
[20]Cui, C (Cui, Cheng), XB (Li, Xiaobei), Liang, H (Liang, Hao), Hou, Z (Hou, Zhe), Tu, SQ (Tu, Siqi), Dong, ZQ (Dong, Zhongqi), Yao, XT (Yao, Xueting), M (Zhang, Miao), Zhang, X (Zhang, Xuan), Li, HY (Li, Haiyan), Liu, DY (Liu, Dongyang).Physiologically based pharmacokinetic model of renally cleared antibacterial drugs in Chinese renal impairment patients.BIOPHARMACEUTICS & DRUG DISPOSITION, 2021
total37 1/2
first
previous
next
last
Page
